Troculeucel, a cryopreserved autologous, non-genetically modified NK cell product, appears to cross the blood brain barrier (BBB) via CXCR3, to reduce neuroinflammation via a simple IV administration. Troculeucel was shown to internalize and digest amyloid and α-synuclein proteins in vitro and to improve CSF levels of amyloid, α-synuclein, and p-tau in Phase 1 patients in a largely dose-dependent manner. Troculeucel identifies and eliminates auto-activated T cells without disrupting resting T cells in vitr ...

Core Viewpoint - NKGen Biotech, Inc. is advancing its innovative NK cell therapeutics, particularly focusing on the presentation of preliminary results for its troculeucel therapy in treating moderate Alzheimer's disease at the upcoming AD/PD™ 2025 conference [1][3]. Company Overview - NKGen Biotech is a clinical-stage biotechnology company based in Santa Ana, California, specializing in the development and commercialization of autologous and allogeneic NK cell therapeutics [6]. - The company is developing troculeucel, a novel patient-specific NK cell immunotherapeutic drug candidate, for neurodegenerative disorders and various cancers [5]. Conference Participation - Paul Y. Song, M.D., the CEO of NKGen, will present at the AD/PD™ 2025 conference, which is a significant event for discussing advancements in Alzheimer's and Parkinson's research [1][2]. - The conference is expected to attract over 4,700 participants from more than 70 countries, showcasing 2,250 abstracts in 2024 [2]. Presentation Details - The presentation titled "Preliminary Cognitive Improvement in Phase 1 Cohort of Moderate Alzheimer's Disease Subjects Treated with Autologous Natural Killer Cells (Troculeucel; SNK01)" will take place on April 5, 2025, focusing on three-month cognitive and biomarker results from the Phase 1 cohort of the clinical trial [3]. - New data from the six-month analysis of this cohort will also be discussed during the presentation [3]. Product Information - Troculeucel, also known as SNK01, has received the International Nonproprietary Name (INN) approval from the World Health Organization (WHO), marking a significant milestone for NKGen in bringing this therapy to market [5].